Key result
TAVR improves quality of life by ~18 points at 3 months regardless of sarcopenia status.
Why the study?
Sarcopenia is the core component of frailty, but its role in patients undergoing TAVR remains a matter of debate.
Does transcatheter aortic valve replacement improve quality of life in sarcopenic compared to non-sarcopenic patients with severe aortic stenosis?
Cohort (n=99)
No
Does transcatheter aortic valve replacement improve quality of life in sarcopenic compared to non-sarcopenic patients with severe aortic stenosis?
TAVR significantly improves quality of life at 3 months in patients with severe aortic stenosis, regardless of baseline sarcopenia status.
Background: Sarcopenia is the core component of frailty; however, its role in patients undergoing transcatheter aortic valve replacement (TAVR) is a matter of debate. The Toronto Aortic Stenosis Quality of Life Questionnaire (TASQ) is a validated instrument for assessing quality of life (QoL) in patients with severe aortic stenosis (AS). Aims: We aim to evaluate the QoL of sarcopenic and non-sarcopenic patients with severe AS undergoing TAVR. Methods: TASQ was prospectively administered to patients undergoing TAVR. All patients completed the TASQ before TAVR and at a 3-month follow-up. The study population was divided in two groups according to sarcopenic status. The primary endpoint was the TASQ score in the sarcopenic and non-sarcopenic cohorts. Results: In total, 99 patients were eligible for the analysis. In both sarcopenic (n = 56) and non-sarcopenic (n = 43) cohorts, significant changes were observed in the overall TASQ score and in all but one (i.e., health expectations) of the individual domains (p < 0.01). Sarcopenic and non-sarcopenic patients showed substantial improvements across TASQ subscores. The mean change in overall TASQ score at three months revealed a significant improvement in both cohorts (p < 0.01). Health expectations worsened in sarcopenic patients at the 3-month follow-up (p = 0.06). Conclusions: The TASQ questionnaire revealed changes in QoL after TAVR, regardless of patients’ sarcopenic status. Health status improved substantially in both sarcopenic and non-sarcopenic patients following TAVR. Lack of improvement in health expectations seems to depend on patients’ expectations regarding the procedure and specific aspects in the evaluation of the outcome.
No takes yet. Share an insight, caveat, or question.
Pesarini et al. (2023) conducted a cohort in Severe symptomatic aortic valve stenosis (n=99). Sarcopenia vs. Non-sarcopenic status was evaluated on Mean change in overall TASQ (Toronto Aortic Stenosis Quality of Life Questionnaire) score at 3 months (p=<0.01). Quality of life significantly improved 3 months after TAVR in both sarcopenic (+18.6 points) and non-sarcopenic (+18.32 points) patients with severe aortic stenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: